LTP001 clinical trials
Also written LTP001.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses LTP001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LTP001
- 3
Studies by the year they started
3 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses LTP001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension ParticipantsTerminatedPhase 2Novartis PharmaceuticalsNCT05764265Written as LTP001
- To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPFTerminatedPhase 2Novartis PharmaceuticalsNCT05497284Written as LTP001
- Study of Efficacy and Safety of LTP001 in Pulmonary Arterial HypertensionTerminatedPhase 2Novartis PharmaceuticalsNCT05135000Written as LTP001